{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Girard N"],"pubmed_abstract":["<h4>Background</h4>Consolidation durvalumab is standard of care treatment for patients with unresectable, stage III non-small-cell lung cancer without progression after chemoradiotherapy. Additional study is warranted to investigate the long-term efficacy of this regimen in real-world settings.<h4>Methods</h4>PACIFIC-R (NCT03798535) was an international, observational, cohort study of patients who started durvalumab 10 mg/kg intravenously every 2 weeks within an AstraZeneca-initiated early access program between September 2017 and December 2018. Data were extracted retrospectively from medical records to describe the real-world effectiveness of consolidation durvalumab in patients with unresectable non-small-cell lung cancer without progression after chemoradiotherapy. The primary endpoint"],"journal":["ESMO open"],"pagination":["106070"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12919254"],"repository":["biostudies-literature"],"pubmed_title":["Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC."],"pmcid":["PMC12919254"],"pubmed_authors":["McDonald F","Shcherbakova T","Mornex F","Garassino MC","Chander P","Diaz Perez I","Moskovitz M","Peters S","Haakensen VD","Bar J","Fietkau R","Solomon B","Christoph DC","Kao S","Gregorc V","Filippi AR","Baas P","Girard N","Garrido Lopez P","Anand S","Hiltermann TJN","Chouaid C","Qiao Y","Siva S","Field JK"],"additional_accession":[]},"is_claimable":false,"name":"Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.","description":"<h4>Background</h4>Consolidation durvalumab is standard of care treatment for patients with unresectable, stage III non-small-cell lung cancer without progression after chemoradiotherapy. Additional study is warranted to investigate the long-term efficacy of this regimen in real-world settings.<h4>Methods</h4>PACIFIC-R (NCT03798535) was an international, observational, cohort study of patients who started durvalumab 10 mg/kg intravenously every 2 weeks within an AstraZeneca-initiated early access program between September 2017 and December 2018. Data were extracted retrospectively from medical records to describe the real-world effectiveness of consolidation durvalumab in patients with unresectable non-small-cell lung cancer without progression after chemoradiotherapy. The primary endpoint","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T09:45:09.09Z","creation":"2026-07-09T10:47:24.453Z"},"accession":"S-EPMC12919254","cross_references":{"pubmed":["41643268"],"doi":["10.1016/j.esmoop.2026.106070"]}}